Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.54, $0.09 better than the analyst estimate of $0.45. Revenue for the quarter came in at $204 million versus the consensus estimate of $201.47 million.

Outlook:-
FY 2026 EPS between $2.03-$2.09 vs consensus $2.

For earnings history and earnings-related data on Repligen (RGEN) click here.